Live news , top stories, corporate news, company news, sector news, economy news, results analysis news, ceo interviews, fund manager interview, advisor interview, market news, bazaar talk, hot stocks news, ipo news, commodities news, mutual fund news, insurance news, news wire
18 November, 2017 08:23 IST
Zydus receives USFDAs final nod for Eletriptan HCl tablets
Source: IRIS | 19 Jun, 2017, 10.32AM
Comments  |  Post Comment

Zydus Cadila has received the final approval from the US Food and Drug Administration (USFDA) to market Eletriptan Hydrobromide Tablets, 20 mg (base) and 40 mg (base).

The drug which is used in the treatment of migraine will be produced at the group’s formulations manufacturing facility at the Pharma SEZ in Ahmedabad.

The group now has more than 120 approvals and has so far filed over 300 ANDAs since the commencement of the filing process in FY 2003-04.

Shares of the company gained Rs 7.15, or 1.36%, to trade at Rs 532.55. The total volume of shares traded was 33,144 at the BSE (10.24 a.m., Monday).



Cadila Healthcare Limited   (Q,N,C,F)*

Comments Post comment 
 Post Comment
Name Email
Comment
Security Code type    into this box
Company Update
Tata Communications joins hands with The European Tour - 17-Nov-2017 10:27
Hinduja Ventures enters into agreements to hike stake in HLFL - 17-Nov-2017 10:23
Cipla receives final approval for generic Pulmicort Respules - 17-Nov-2017 10:16
Tata Power raises Rs 15 bn on private placement basis - 17-Nov-2017 10:09
Indian Navy signs contract with Tata Power for supply of PDDS - 17-Nov-2017 10:06
ICICI Bank, Paytm tie-up to offer short term instant digital credit - 17-Nov-2017 10:00
Wipro launches industry-specific solutions on SAP Leonardo - 17-Nov-2017 09:56
Infosys in collaboration with ATP launches Second Screen - 17-Nov-2017 09:52
Tata Motors joins hands with Energy Efficiencies Services - 16-Nov-2017 12:31
Ahluwalia Contracts bags orders worth Rs 3.11 bn - 16-Nov-2017 11:30
Suven Life Sciences secures product patents in HK, India and USA - 16-Nov-2017 11:27
more...
Home  |   Shares  |   F&O  |   Mutual Funds  |   Loans  |   Insurance  |   News Centre
Wealth Tracker  |   Newsletters  |   Tax Corner  |   NRI Centre  |   Advertise
© All rights reserved. IRIS Business Services Limited
A Disclaimer